Skip to main content

Table 2 The mean (standard deviation) scores of ABC subscales in the N-Acetylcysteine + risperidone group and Placebo+risperidone group

From: A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders

Subscale Group Baseline score One month after the onset of intervention Two months after the onset of intervention Between groups difference
Irritability N-Acetylcysteine + risperidone 13.2(5.3) 10.0(4.1) 9.7(4.1) F1,29= 4.9, P<0.035
Placebo+Risperidone 16.7(7.8) 15.5(7.9) 15.1(7.8)
Hyperactivity and Noncompliance N-Acetylcysteine + risperidone 29.3(6.4) 21.4(7.7) 18.3(6.9) F1,29= 2.4, P=0.12
Placebo+Risperidone 31.9(8.9) 26.8(11.0) 24.3(12.1)
Lethargy and Social Withdrawal N-Acetylcysteine + risperidone 11.9(6.5) 9.0(5.7) 8.5(6.5) F1,28= 0.4, P=0.53
Placebo+Risperidone 12.2(8.3) 11.0(7.8) 10.9(7.5)6
Stereotypic Behavior N-Acetylcysteine + risperidone 6.6(4.5) 4.5(3.6) 3.9(2.7) F1,28= 2.8, P=0.1
Placebo+Risperidone 8.5(6.3) 7.7(6.2) 7.8(6.6)
Inappropriate Speech N-Acetylcysteine + risperidone 3.9(3.7) 3.8(3.7) 3.2(3.4) F1,29= 1.8, P=0.1
Placebo+Risperidone 5.7(3.8) 5.3(3.7) 5.2(4.0)